je.st
news
Dr. Reddy Is Transitioning From A Pure Generic Player To An Innovator
2016-02-18 00:09:33| Biotech - Topix.net
Currently it is just the warning letter that is at the top of everybody's mind when it comes to investing in Dr. Reddy. By 2022, Proprietary product business alone should contribute about INR 70 per share to the EPS.
Tags: to
player
pure
generic
Category:Biotechnology and Pharmaceuticals